Combination efficacy looks similar to Kura’s, but adverse events with revumenib could raise concerns again.

More details on cardiovascular events with the group’s anti-CD47 project comforted analysts, but shares still fell 10%.

The group's enthusiasm is backed by an academic trial of INB-100 in 10 AML patients.

An early study of the group’s anti-CD47 project SL-172154 has seen waning efficacy, a heart attack and a death.

The company’s long-delayed pivotal trial is hit by a stronger-than-expected placebo performance.

The company reckons its tech could solve problems with current ADCs, but the market isn’t giving it much credit yet.

The company makes no secret of the need for durability with its anti-CD47 project SL-172154.